Open Access. Powered by Scholars. Published by Universities.®

Biochemistry, Biophysics, and Structural Biology Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 3 of 3

Full-Text Articles in Biochemistry, Biophysics, and Structural Biology

Neutron Radiography With Combined Computed Tomography: A Novel Tool For Cancer Diagnosis And Imaging (Abstract), Maria Cekanova, H Bilheux, Kusum Rathore, J Bilheux, L Walker, Robert Donnell, Alfred Legendre May 2013

Neutron Radiography With Combined Computed Tomography: A Novel Tool For Cancer Diagnosis And Imaging (Abstract), Maria Cekanova, H Bilheux, Kusum Rathore, J Bilheux, L Walker, Robert Donnell, Alfred Legendre

Alfred M Legendre DVM, MS, DACVIM

No abstract provided.


Preclinical Single-Dose Safety And Pharmacokinetic Evaluation Of Fluorocoxib A: Pilot Study Of Novel Cyclooxygenase-2-Targeted Optical Imaging Agent In A Canine Model, Maria Cekanova, M Uddin, Alfred Legendre, Gina Gaylon, Joseph Bartges, Amanda Callens, L Marnett May 2013

Preclinical Single-Dose Safety And Pharmacokinetic Evaluation Of Fluorocoxib A: Pilot Study Of Novel Cyclooxygenase-2-Targeted Optical Imaging Agent In A Canine Model, Maria Cekanova, M Uddin, Alfred Legendre, Gina Gaylon, Joseph Bartges, Amanda Callens, L Marnett

Alfred M Legendre DVM, MS, DACVIM

We evaluated preclinical single-dose safety, pharmacokinetic properties, and specific uptake of the new optical imaging agent fluorocoxib A in dogs. Fluorocoxib A, N-[(5-carboxy-X-rhodaminyl)but-4-yl]-2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetamide, selectively binds and inhibits the cyclooxygenase-2 (COX-2) enzyme, which is overexpressed in many cancers. Safety pilot studies were performed in research dogs following intravenous (i.v.) administration of 0.1 and 1  mg/kg fluorocoxib A. Blood and urine samples collected three days after administration of each dose of fluorocoxib A revealed no evidence of toxicity, and no clinically relevant adverse events were noted on physical examination of exposed dogs ...


Molecular Characterisation Of Canine Nonsteroidal Anti-Inflammatory Drug-Activated Gene (Nag-1), K Yamaguchi, Nichelle Whitlock, Jason Liggett, Alfred Legendre, Michael Fry, Seung Baek Dec 2010

Molecular Characterisation Of Canine Nonsteroidal Anti-Inflammatory Drug-Activated Gene (Nag-1), K Yamaguchi, Nichelle Whitlock, Jason Liggett, Alfred Legendre, Michael Fry, Seung Baek

Alfred M Legendre DVM, MS, DACVIM

Nonsteroidal anti-inflammatory drug (NSAID)-activated gene (NAG-1), a divergent member of the transforming growth factor beta superfamily, was previously identified as a gene induced by several anti-tumorigenic compounds, including NSAIDs and peroxisome proliferator-activated receptor gamma (PPARgamma) ligands in humans. In this study, canine NAG-1 was characterised from a canine genomic database. Gene induction by some NSAIDs and PPARgamma ligands was demonstrated in canine osteosarcoma cell lines. Phylogenetic analysis indicates that canine NAG-1 is more homologous with the corresponding mouse and rat genes than with human NAG-1. Expression of canine NAG-1 was increased by treatment with piroxicam and SC-560 (NSAIDs) and ...